NCT06916793View on ClinicalTrials.gov

A Phase 3 Study to Evaluate the Safety and Efficacy of CKD-843 in Male Patients With Androgenetic Alopecia

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

288

Participants

Timeline

Start Date

April 30, 2025

Primary Completion Date

December 19, 2026

Study Completion Date

September 17, 2027

Conditions
Androgenetic Alopecia
Interventions
DRUG

CKD-843 dose#1

IM injection every 3 months for 12 months

DRUG

CKD-843 dose#2

IM injection every 3 months for 12 months

DRUG

Placebo of CKD-843 dose

IM injection every 3 months for 12 months

DRUG

Dutasteride Capsules

oral, once daily, 12 months

DRUG

Placebo of Dutasteride Capsule

oral, once daily, 12 months

Trial Locations (1)

Unknown

Seoul National University Hospital, Seoul

Sponsors
All Listed Sponsors
lead

Chong Kun Dang Pharmaceutical

INDUSTRY

NCT06916793 - A Phase 3 Study to Evaluate the Safety and Efficacy of CKD-843 in Male Patients With Androgenetic Alopecia | Biotech Hunter | Biotech Hunter